By Jesse Greenspan ( February 22, 2008, 12:00 AM EST) -- The number of reverse-payment agreements is going up, and courts have generally been reluctant to declare them anti-competitive. In filing a lawsuit against Cephalon Inc. earlier this month, though, the U.S. Federal Trade Commission showed it is not yet giving up the fight against the controversial patent settlements between brand-name and generics drug companies....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.